LONDON - Autolus Therapeutics plc (NASDAQ:AUTL), a biopharmaceutical company specializing in programmed T cell therapies with a market capitalization of $883 million, has announced that the New England Journal of Medicine published results from its FELIX study of obecabtagene autoleucel (obe-cel) in adult B-cell Acute Lymphoblastic Leukemia (ALL). According to InvestingPro data, the company maintains a strong financial position with more cash than debt on its balance sheet. The study found a 76.6% complete remission rate in patients treated with obe-cel, with a median follow-up of 20.3 months.
The FELIX study enrolled 153 relapsed/refractory B-ALL patients, with 127 receiving at least one infusion of the treatment. The primary endpoint was overall remission, which was achieved at high rates, and the therapy was associated with low incidence of severe immune-related toxicity. With revenue growth of 83% in the last twelve months and analysts projecting continued sales growth, InvestingPro analysis suggests the company is positioned for expansion despite currently operating at a loss. Only 2.4% of patients experienced Grade ≥3 cytokine release syndrome (CRS), and 7.1% developed immune effector cell-associated neurotoxicity syndrome (ICANS).
The data indicate that obe-cel may provide a significant clinical benefit with a durable response, especially in patients with low-intermediate bone marrow burden. These findings suggest a potential shift in the standard of care for adult relapsed/refractory B-ALL.
Patients with varying levels of bone marrow burden before treatment showed different outcomes. Those with lower levels had a 12-month event-free survival rate of 68.0%, while those with higher levels had a rate of 25.0%. The median overall survival for all infused patients was 15.6 months.
Regarding safety, the majority of CRS and ICANS cases were not severe. Intensive care was required for 15.7% of patients, with a median stay of 5.5 days.
Obe-cel, now FDA-approved under the name AUCATZYL, is also being reviewed by European and UK regulators, with submissions accepted in March and August 2024 respectively.
The study's results are based on a press release statement from Autolus Therapeutics plc. The company is known for developing next-generation T cell therapies aimed at treating cancer and autoimmune diseases. Their FDA-approved product AUCATZYL, along with other candidates, represents their commitment to advancing cancer treatment options. The stock has shown significant momentum with an 11% return over the past week, though investors should note its beta of 2.04 indicates higher volatility than the market. For detailed financial analysis and 12 additional ProTips, visit InvestingPro, where you can access comprehensive research reports covering 1,400+ US stocks.
In other recent news, Autolus Therapeutics has seen a wave of positive developments. The company's cell therapy product, obe-cel, received approval, marking it as the first of its kind approved without a risk monitoring program. This early approval has sparked optimism for the product's commercial potential, leading Redburn-Atlantic to upgrade Autolus's stock from Neutral to a Buy rating and setting a new price target at $13.00.
In addition to the obe-cel approval, Autolus also reported FDA approval of AUCATZYL, a significant development for the treatment of relapsed or refractory Acute Lymphoblastic Leukemia. Despite reporting increased operating expenses and a net loss for the third quarter of 2024, the company maintains a substantial cash reserve of $657.1 million and anticipates future milestone payments and regulatory approvals.
These recent developments have positioned Autolus to potentially outperform expectations and deliver on its commercial promises. The company is expanding its network of treatment centers and advancing its pipeline with new studies and programs. Autolus also expressed optimism about the potential for outpatient administration of obe-cel and is on track for EU approval by mid-2025. These are the latest updates in the company's operations, providing a glimpse into its recent progress.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.